泌尿生殖系统癌症患者对二硝基氯苯的皮肤反应。

Cutaneous response to dinitrochlorobenzene in patients with genito-urinary cancers.

作者信息

Duclos H, Schwarzenberg L, Duclos S H, Hugues H, Kuss R

出版信息

Biomedicine. 1977 Jan 31;27(1):43-7.

Abstract

The aim of the present study is to analyse the response in patients with cancer of the urogenital region to a primary antigen 2-4 dinitrochlorobenzene (DNCB). A total of 69 patients with neoplastic disease were studied (13 cases with kidney cancer, 34 cases with bladder cancer, 13 cases with prostatic cancer, 5 cases with testicular cancer, one case with penis cancer, and 3 cases with cancer of the cervix, comparatively with 13 patients with non-malignant urological diseases. Whereas in the control group, 78% of the patients gave a positive skin reaction to DNCB, 15% of the patients with kidney cancer, 56% of the patients with bladder cancer, 69% of the patients with prostatic cancer and 60% of the patients with testicular cancer gave a positive reaction. If we consider the stages of the disease, the reaction was positive, in 91% of bladder cancer at stage I and in 47% at stages II and III in 100% of prostatic cancer at stage I and in 62% at stages II and III, in 60% of testicular cancer at stage IV (but 100% of seminomas and 0% of dysembryomas have a positive reaction). It would therefore seem that a correlation exists between the degree of the extension of the disease and the skin reaction to DNCB.

摘要

本研究的目的是分析泌尿生殖系统癌症患者对原发性抗原2,4 - 二硝基氯苯（DNCB）的反应。共研究了69例肿瘤疾病患者（13例肾癌、34例膀胱癌、13例前列腺癌、5例睾丸癌、1例阴茎癌和3例宫颈癌），并与13例非恶性泌尿系统疾病患者进行对比。在对照组中，78%的患者对DNCB有阳性皮肤反应，而肾癌患者中有15%、膀胱癌患者中有56%、前列腺癌患者中有69%、睾丸癌患者中有60%有阳性反应。如果考虑疾病分期，I期膀胱癌患者中有91%反应为阳性，II期和III期患者中有47%；I期前列腺癌患者中100%反应为阳性，II期和III期患者中有62%；IV期睾丸癌患者中有60%（但精原细胞瘤为100%，胚胎癌为0%有阳性反应）。因此，疾病的扩展程度与对DNCB的皮肤反应之间似乎存在相关性。